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Abstract
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This study uses high-pressure size exclusion chromatography (HPSEC) to quantify divalent metal
ion (X2+)-induced compaction found in vitamin K dependent (VKD) proteins. Multiple X2+
binding sites formed by the presence of up to 12 -carboxyglutamic acid residues (Gla) are present
in plasma-derived (pd-) and recombinant (r-) Factor IX (FIX). Analytical ultracentrifugation
(AUC) was used to calibrate the Stokes radius (R) measured by HPSEC. A compaction of pd-FIX
caused by the filling of Ca2+ and Mg2+ binding sites resulting in a 5-6% decrease in radius of
hydration as observed by HPSEC. The filling of Ca2+ sites resulted greater compaction than for
Mg2+ alone where this effect was additive or greater when both ions were present at physiologic
levels. Less X2+ induced compaction was observed in r-FIX with lower Gla content populations
which enabled the separation of biologically active from inactive r-FIX species by HPSEC.
HPSEC was sensitive to R changes of ~0.01 nm that enabled the detection of FIX compaction that
was likely cooperative in nature between lower avidity X2+ sites of the Gla domain and higher X2+
avidity sites of the EGF1-like domain.
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1. Introduction
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The Vitamin K-dependent (VKD) family of plasma proteins are key participants in the
coagulation cascade of hemostasis[1,2]. This family includes the anticoagulant proteins C, S
and Z, and the procoagulant factors (F) VII, IX, X and prothrombin [3]. The first nine amino
terminal glutamic acids of these glycoproteins are well conserved and are -carboxylated to
form “γ-carboxyglutamic acid (Gla) residues”. These residues are part of the “Gla domain”
which contains 7-8 divalent metal (X2+) binding sites that are essential to the function of
VKD coagulation proteins. This function is highly regulated by the formation of multiprotein complexes at the phospholipid surfaces of injured vascular endothelium. A spatially
quantitative measure of overall holoprotein folding as a function X2+ site filling would
provide insight into the process by which coagulation protein complexes are formed.
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The conformational attributes of the Gla domain have been well studied using NMR and xray crystallography [4-9]. Since VKD proteins are also glycoproteins the Gla domain is
usually isolated to enable study by crystallography. The Gla domain has also been studied
using X2+, conformational-dependent monoclonal antibodies [10-14]. These previous
studies have observed the cooperative folding within the Gla domain that occurs with filling
of Ca2+- and Mg2+-binding sites [4,5,8,15]. Conformational changes have been also
observed in all the VKD coagulation proteins using fluorescence quenching due to specific
X2+ site binding [8,16,17]. FIX is an example of a VKD protein with X2+ binding sites not
only in the Gla domain but it also contains two additional Gla residues that help to form an
additional Mg2+ site [18-20]. FIX also contains a Ca2+ site in one of two epidermal growth
factor-like domains and also in its C-terminal serine protease domain [1,2].

Author Manuscript

Recombinant biosynthesis of VKD proteins frequently results in subpopulations of partially
carboxylated proteins with modified structure and function [19,21-24]. As with other VKD
proteins, recombinant (r-) FIX has important uses as a biotherapeutic where partially and
fully -carboxylated structures yield different biological activity [19,24]. The high-pressure
size exclusion chromatography (HPSEC) method presented here provides a quantitative
assessment of overall changes in VKD macromolecular extension due to filling of the Ca2+
and Mg2+ sites that can be directly correlated with in vitro coagulation activity. This
technique is demonstrated using plasma-derived (pd-) FIX with a full complement of 10
total X2+ binding sites that is compared to r-FIX populations with less γ-carboxylation.

2. Experimental
2.1. Reagents
All buffer components were purchased from VWR International LLC (Radnor, PA, USA) or
Thermo Fisher Scientific (Waltham, MA, USA) or Sigma (St. Louis, MO, USA) unless
otherwise stated. In order to minimize degradation, purification processes were performed at
Anal Biochem. Author manuscript; available in PMC 2016 June 15.
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4°C. The stocks of pd, immunoaffinity purified, therapeutic grade FIX (Mononine, CSL
Behring, USA) were expired for clinical use, but when used in experiments, exhibited full
procoagulant activity (150-250 U/mg). Human FIX from the milk of transgenic swine (rFIX) was purified using a modified version of the procedure of Lindsay et al. [25]. HPSEC
was used to isolate the purified sample into low carboxylated zymogen r-FIX that was
inactive (<10 U/mg), zymogen r-FIX that had native coagulation activity (150-200 U/mg),
and activated r-FIX (r-FIXa) (>3000 U/mg). Inactive and active r-FIX contained no r-FIXa
according to SDS-PAGE. All activities were confirmed by one-stage clotting assay [25-27].
2.2. High-Pressure Size Exclusion Chromatography

Author Manuscript

The FIX products were concentrated and exchanged into 20 mM Tris, 200 mM NaCl, pH
7.0 (running buffer) using an Amicon Ultra 10 kDa molecular cut off centrifugal filter
(Millipore, Billerica, MA, USA). The running buffers were treated with the sodium form of
Chelex Analytical Grade 100 resin (Bio-Rad Laboratories, Hercules, CA USA) to remove
X2+ contamination. Some studies used running buffer that contained CaCl2 and or MgCl2
which was added after Chelex 100 resin treatment. All injected samples were formulated
with Chelex treated buffer. All sample injection volumes were less than 50 μL, and were
diluted by a factor of at least 10-fold by the 500 μL buffer volume in the sample loop. The
FIX products were loaded onto a 60 cm X 2.15 cm I.D. TSK gel G3000SW column (Tosoh
Bioscience, King of Prussia, PA, USA) equipped with a guard column and a pre-filter.
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Briefly, the chromatography was performed on the Knauer (Berlin, Germany) Smartline
chromatography station described above. Flow rate was set at a constant 0.5 mL/min and the
run length was 45 minutes for all studies. Effluent's absorbance was measured at an
absorbance of 280 nm. Samples were run in triplicates and the center of the elution peaks
were used to calculate residence time (with standard deviation <0.016). All elution volumes
can be found by multiplying the elution time by 0.5 mL/min.
2.3. Sodium Dodecylsulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE)
Samples were analyzed by SDS-PAGE stained with colloidal Blue gel stain (Invitrogen,
Carlsbad, CA, USA) using Invitrogen Novex precast gels and the Invitrogen Surelock XL
apparatus. All gels were NuPage 12% Bis-Tris run with 2-(N-morpholino) ethanesulfonic
acid (MES) running buffer (Invitrogen). Briefly, samples were mixed with 4x LDS sample
buffer (Invitrogen) and deionized water followed by heating at 75 °C for 10 min. For
reduced gels, samples were mixed with 10x reducing agent (Invitrogen) prior to heating.
2.4. Analytical Ultracentrifuge
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pd-FIX in 0.15 M NaCl, 50 mM Tris, pH 7.5 with either 10mM EDTA or CaCl2 and/or
MgCl2 was examined by sedimentation velocity in a Beckman Optima XL-A analytical
ultracentrifuge at 52,000 or 55,000 rpm and 20 °C in 12 mm path length double sector cells
using absorption optics at 280 nm. All samples were at the same protein concentration, 0.3
mg/ml. Apparent sedimentation coefficient distributions, uncorrected for diffusion, were
determined as g(s) plots using the Beckman Origin based software (Version 3.01). These
plots display a function proportional to the weight fraction of material with a given
sedimentation coefficient, s. The function g(s) was calculated as:
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where s is the sedimentation coefficient, ω is the angular velocity of the rotor, co is the initial
concentration, r is the radius, rm is the radius of the meniscus, and t is time. The x-axis is
converted to sedimentation coefficient by:
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These plots display a function proportional to the weight fraction of material with a given
sedimentation coefficient, s [28]. The S20,w values were calculated using a partial specific
volume which was corrected to a value of 0.708 as determined by the amino acid and
carbohydrate composition of FIX [29,30]. The Stokes radius (R) was calculated using a
molecular weight of 62,800. R is inversely proportional to the sedimentation coefficient,
S20,w, where compaction of the pd-FIX increases the sedimentation coefficient. Specifically,
the sedimentation coefficient was used to calculate R defined by the relationship:

where M is the molecular weight, Ṽ is the partial specific volume, ρ is the solvent density,
N is Avogadro's Number and η is the viscosity [31].
2.5. Modeling of X2+ Free and Bound pd-FIX
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The X2+ equilibrated solution structures of pd-FIX were obtained from Perera [32]. The
MODELLER program [33] was employed to model the X2+ free pd-FIX holoprotein by
additionally utilizing NMR structures reported for pd-FIX Gla domain (PDB ID: 1CFX, [8])
as templates. No molecular shape was apriori assumed as part of the model. The built
models were further refined by energy minimization using the CHARMM program with
CHARMM19 force field [34] consisting of 50 steps of Steepest Descent, followed by 500
steps of Adopted Basis Newton-Raphson. Harmonic restraints of 10 kcal/mol/Å2 were
applied on the Cα atoms of the protein during the entire minimization.
2.6. Mass Spectrometry of the Gla Domain
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The γ-carboxylation of the Gla domain of pd-FIX and r-FIX were assessed using LC-ESITOF mass spectrometry (MS). Samples of r-FIX and active r-FIX were activated with
Factor XIa (FXIa) (Haemtech, Essex Junction, VT) using a 1:100 (w:w) enzyme to substrate
ratio in 5mM CaCl2, 1X TBS, pH 7.4 at 37°C for 1.0 hour. After activation, the samples
were quenched with 1.2 moles of EDTA per mole of calcium and stored at -80°C until
further analysis.
MS analysis was performed on an Agilent 1200 capLC system with an Agilent 6210 ESITOF MS [35]. Solvent A was 0.1% formic acid (Fluka) (v/v) in deionized water. Solvent B
was 0.1% formic acid (v/v) in acetonitrile (Burdick and Jackson). The column was an
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Agilent 300SB-C8 Poroshell column: 7.5 cm L x 0.5 mm ID, 5 micron particle size. MS
data were acquired with MassHunter in positive mode with the following parameters: 4000
V source voltage, 325°C nebulizing gas temperature, 7 L/min gas flow rate, internal
reference mass of 922.01 m/z. MS data were analyzed using Agilent's Qualitative Analysis
(version B.01.03).
2.7 One stage coagulation assay

Author Manuscript

FIX specific activity was determined using a one stage coagulation assay [36]. Briefly, 50
μL each of PTT Automate 5 reagent (Diagnostica Stago, Inc., Parsippany, NJ, USA), 50 μL
of FIX deficient plasma (George King Bio-Medical, Overland Park, Kansas, USA), or 50 μL
sample was added to the measurement cuvette and incubated at 37 °C for 3 min. After the
incubation period, 50 μL of 25 mM CaCl2 was added and the clotting time was measured
using the STart Hemostasis Analyzer (Diagnostica Stago, Inc., Parsippany, NJ). Normal
human plasma (Diagnostica Stago, Inc., Parsippany, NJ) was used as the defined standard
reference where normal human plasma contains 1 international unit of FIX clotting activity
per mL. The concentration of purified r-FIX was determined spectrophotometrically at 280
nm using an extinction coefficient, ε1% =13.4.

3. Results and discussion
3.1. Predicted holoprotein size changes in pd-FIX induced by X2+
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Herein, we use HPSEC calibrated by AUC to quantitatively measure holoprotein folding
contributed by different domains due to the filling of both Ca2+/Mg2+ sites relative to Ca2+
and Mg2+sites alone. Molecular modeling of X-ray crystallography and NMR data was used
to help predict the nature and magnitude of the holoprotein size change that would be
expected from the filling of all X2+ sites within different domains of FIX. The predicted
structures of X2+ free and bound of FIX containing the full complement of 12 Gla residues
are shown in Fig. 1. In the presence of physiologic levels of Ca2+ (~1.1 mM) and Mg2+
(~0.6 mM), four sites (numbered 2, 3, 5 and 6) are occupied by Ca2+ and three (numbered 1,
4, and 7) by Mg2+ [4,37]. It is important to note that all metal sites in the Gla domain will be
filled by Ca2+ at greater than 2 mM in the absence of Mg2+. The Mg2+-site 4 is predicted to
switch to Ca2+ upon binding of the Gla domain to phospholipid (PL) [38].

Author Manuscript

Our modeling predicted a linear structure with a more extended structure in the case of
vacant relative to X2+ filled sites. Our model predicted an overall radius of gyration (Rg) of
34.46 Å for the X2+ free state and 32.75 Å for the X2+ filled pd-FIX holoprotein with a
relative change in Rg of ~5%. As expected, the largest contributor to changes in molecular
extension arose from the filling of both Ca2+ and Mg2+ sites in the core Gla domain (Fig.
1A, 1B). Currently, there is a lack of crystallographic data that studies the Gla domain under
conditions having only Mg2+ filled sites.
Interestingly, other more subtle changes with X2+ dependent conformation were predicted
by our model which were caused by domains outside of core Gla domain. For example, the
Gla residues at amino acid 36 and 40 do not affect FIX biological activity in vitro [19] and
are not present in other VKD proteins. Recombinant biosynthesis frequently results in the
lack of γ-carboxylation at these two positions and therefore the inability to form the number
Anal Biochem. Author manuscript; available in PMC 2016 June 15.
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eight X2+ site that is Mg2+-specific [7,19]. Our model also predicts that the Ca2+ specific
binding site which occurs in the EGF1-like domain [39] will be the next largest contribution
to the overall compaction of pd-FIX relative to the Gla domain. The Ca2+ specific site in the
protease domain [40,41] was predicted to give a negligible contribution to pd-FIX
compaction.
3.2. Homogeneity of the pd-FIX and rFIX preparations studied here

Author Manuscript

Previous studies have reported protein aggregation in pd-FIX in the presence of X2+
observed by AUC at concentrations of >0.3 mg pd-FIX/ml [16]. Thus, we used SDS-PAGE
and HPSEC to ascertain the extent of aggregation in the pd-FIX and r-FIX preparations
studied here. For example, Fig. 2A shows SDS-PAGE analysis under non-reducing
conditions of immunoaffinity purified, therapeutic grade pd-FIX where an estimated 100 ng
band at 47 kDa was observed. This subpopulation of proteolyzed FIX is commonly present
in pd-FIX and has a 10 kDa fragment removed from its carboxy- terminus [42]. Thus, we
estimate that the pd-FIX here contained >95% zymogen having a Mr of 57 kDa and 0.1-5%
proteolyzed pd-FIX. Fig. 2B and 2C show the typical HPSEC chromatographic profiles for
injections of 25 and 50 μg pd-FIX that was obtained at physiologic pH in the presence of 1.1
mM Ca2+ alone and of 0.6 mM Mg2+ alone, respectively. Fig. 3-5 present the HPSEC
chromatographic behavior for analysis of 100 μg injections. In all cases studied, the HPSEC
behavior possessed a single predominant and symmetrical peak. In the case of the 100 μg
injection, a peak height signal was observed which was about 4- and 2-fold larger than those
observed for the 25 μg and 50 μg injections. Taken together, the samples predominately
contained intact pd-FIX which showed no appreciable tendency to form aggregates at any of
the X2+ and protein concentrations examined here by HPSEC or AUC.
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3.3. HPSEC Elution Profile Sensitivity to pd-FIX size changes resulting from presence of
Ca2+ alone

Author Manuscript

We observed changes in overall HPSEC elution times of FIX in sequence of
chromatographies with incrementally higher Ca2+ levels known to metal site filling in the
higher avidity catalytic and EGF1-like domains followed by the lower avidity Gla domain.
For example, Fig. 3A shows the HPSEC chromatographic profiles for pd-FIX collected over
a range of sub- to supra-physiologic Ca2+ levels in the absence of Mg2+. A baseline
residence time of about 17.1 minutes was obtained for the elution peak of pd-FIX when
chromatographed under X2+ free conditions (Fig. 3A: curve 1). When chromatographed at a
subphysiologic level of 0.5 mM Ca2+ at which higher avidity sites in the catalytic and
EGF-1 like domains should approach being filled [39, 43] the residence time shifted to a
longer time of 17.9 minutes (Fig. 3A: curve 2). This compaction phenomena was observed
to increase with increasing levels of Ca2+ (Figure 3A: curve 3-5) up to a supra-physiologic
concentration of 10 mM Ca2+ where a 19.0 elution peak residence time was observed. An
asymptotic level of lengthening residence times of about 19.05 minutes occurred when pdFIX was chromatographed at 15 mM Ca2+ (Fig. 3A: curve 6). At this supra-physiologic
conditions, each X2+ binding site in the core Gla domain has been previously reported to be
occupied by Ca2+ [38].
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Using a plot of HPSEC elution peak residence times versus Ca2+concentration, the change
in chromatographic behavior seen at different X2+ ion concentrations can be correlated with
the filling of specific sites as measured by other techniques [7,19,39-41,43,44]. Two
compaction regimes were observed by HPSEC. The inset plot of Fig. 3B shows the presence
of a compaction regime occurring at a Ca2+ level of 0-0.5 mM. Our modeling (Figure 1)
predicted that significant compaction would result from filling of the Ca2+ specific site in
EGF1-like domain while a negligible amount of compaction would result from filling of the
Ca2+ site in the catalytic domain. This HPSEC data is a first time direct observation of FIX
holoprotein compaction as a result of the higher affinity Ca2+ sites filling in those domains.
In contrast, a separate compaction regime that was detected at about 0.3 to 5 mM Ca2+ was
consistent with compaction predicted for the core Gla sites. In summary, the compaction
behavior of pd-FIX observed at supra-physiologic levels of Ca2+ is likely the combined
filling of both high avidity Ca2+-specific sites in the EGF1-like and protease domains along
with the lower avidity Ca2+ sites of the Gla domain.
3.4. HPSEC Elution Profile Sensitivity to pd-FIX size changes resulting from presence of
Mg2+ alone
We also observed changes in overall HPSEC elution times of FIX in sequence of
chromatographies with incrementally higher Mg2+ levels known to fill the 3 sites within and
the single site proximal to the core Gla domain. Starkly less compaction was observed in the
presence of Mg2+ alone than that seen for Ca2+ alone (Fig. 4A). For example, the presence
of the physiologic level of 0.6 mM Mg2+ resulted in a decreased, but discernable 0.3 minute
increase in residence time shift over that of X2+ free buffer (Fig. 4A: curves 1 and 2).
Similarly small shifts were observed at the supraphysiologic Mg2+ concentrations of 5 and
10 with no shift detectable at 15 mM Mg2+ (Fig. 4A: curves 3, 4, and 5 respectively).
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A single compaction regime was observed in a plot of the net residence time shift versus
Mg2+ concentration over the range of sub to supra-physiologic levels of Mg2+ (Fig. 4B).
Past studies have shown that all Mg2+-specific sites within the core Gla domain of VKD
coagulation proteins are at least half-maximally filled at physiologic levels of Mg2+ [45].
The compaction response observed by HPSEC seen with Mg2+ relative to Ca2+ is consistent
with the lesser number of Mg2+ sites and their peripheral positioning in the Gla domain (Fig.
1B).
3.5. HPSEC elution profile sensitivity to pd-FIX compaction resulting from presence of
both Mg2+ and Ca2+
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We investigated the dependence of the compacted conformation on the simultaneous
presence of both X2+. In the presence of physiologic levels of both Mg2+ and Ca2+ (Fig. 5:
Curve 4), pd-FIX eluted at later times than that obtained in the presence of no X2+ (Fig. 5:
curve 1), 0.6 mM Mg2+ alone (Fig. 5: curve 2) and 1.1 mM Ca2+ alone (Fig. 5: curve 3).
Importantly, the HPSEC residence time shift resulting from the simultaneous presence of
both X2+ was essentially additive relative to that obtained in the presence of Ca2+ and Mg2+
alone. This is indicative of the respective X2+ specificity of sites which contribute to pd-FIX
compaction.
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It is noted that the compaction of pd-FIX resulting from the filling of the both Ca2+ and
Mg2+ metal binding sites within the Gla domain can be visualized by the organization and
formation of the -loop (Fig. 1B). The -loop has been shown to be an important structure
necessary for biological activity [7,37,38,46]. X2+ sites 2 to 6 strongly affect the positioning
of the -loop which spans amino acids 1-14 and is central to phospholipid binding. Upon
binding of phospholipid, site 4 is converted from a Mg2+ to a Ca2+ site which results in
profound repositioning of the -loop to the interior of the Gla domain [7,38]. Supraphysiologic concentrations of Ca2+ can also result in the filling of site 4 by Ca2+ and a
repositioning of the -loop. In the absence of Mg2+, all sites are occupied by Ca2+ at 2 mM
[38] while at physiologic levels of Ca2+ and Mg2+ positions 1, 4, 7 and 8 are occupied by
Mg2+. However, at supraphysiologic levels at which asymptotic compaction by Ca2+ was
observed here by HPSEC, Mg2+ at site 4 would be displaced by Ca2+ [38].
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3.6. HPSEC observed changes in compaction for partially carboxylated r-FIX
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We investigated the X2+ dependent compaction properties of r-FIX having different extents
of γ-carboxylation and coagulation activity. We observed a difference in the compaction
between high and low Gla content r-FIX at 10 mM Ca2+(Fig. 6). Table 1 presents a
comparison of biotherapeutic grade pd-FIX with the two major HPSEC chromatographic
fractions obtained from a pool of already highly purified r-FIX. Peak 1 possessed the
shortest elution time and it consisted of lower Gla content r-FIX that was inactive. Peak 2
eluted at a longer time and possessed a specific coagulation activity that was comparable to
therapeutic grade pd-FIX. It also predominately consisted of 10-12 -carboxylated Gla
species Gla content r-FIX. The extent of γ-carboxylation in r-FIX has been previously
shown to be a primary determinant of coagulation activity [47,48]. In summary, the inactive
and active r-FIX fractions demonstrated starkly different Ca2+ dependent compaction (Fig. 7
A and B).
We observed similar X2+ dependent compaction regimes for the active r-FIX fraction as that
observed in pd-FIX. In contrast, the inactive r-FIX fraction exhibited a general lack of
compaction. Interestingly, at the level of <0.4 mM Ca2+, the inactive r-FIX fraction
displayed minimal compaction while both the active r-FIX and pd-FIX displayed a similar
but distinguishable compaction. This suggests that the compaction induced by the high
affinity Ca2+ site in the EGF1-like domain which is proximal to the Gla domain is affected
by Gla domain folding. At >0.4 mM Ca2+, the asymptotic maximum in the total residence
time shift was reduced by 82% for inactive r-FIX relative to active r-FIX fractions.
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For chromatographies done in the presence of Mg2+ alone, the compaction of the active rFIX fraction was nearly identical to that of fully -carboxylated pd-FIX. In contrast, the
inactive r-FIX fraction displayed only a <0.05 minute shift in compaction at 0.6-1.1 mM
Mg2+ (Fig. 7 C and D). Thus, this lack of compaction observed using HPSEC indicates that
γ-carboxylation deficiencies likely occurred at positions essential to the formation both Ca2+
and Mg2+ sites within the core Gla domain.
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We used AUC to both confirm the general compaction phenomena and to calibrate the
observed HPSEC chromatographic behavior for the correlative estimation [49-51] of the
Stokes hydrodynamic radius (R) at the X2+ ion concentrations studied here. It is important to
note that past AUC studies of VKD coagulation proteins were used to examine for the
presence or absence of aggregation. Table 2 provides the sedimentation coefficient (s) and
calculated R values which were obtained by AUC for pd-FIX in the absence and presence of
physiologic levels of Ca2+ and Mg2+. We observed an S20,w of 3.72 ± 0.006 Svedburgs
(n=3) by AUC in 10 mM EDTA at 0.3 mg pd-FIX/ml and this translates to an estimated R=
4.35 nm ± 0.006. This contrast previous AUC studies which showed an increase in FIX size
due to aggregation [16]. These studies reported S20,w values were 4.17 Svedburgs for pdFIX measured in the presence of 2 mM EDTA and also for 2.5 mM Ca2+ [16].
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Since the presence of Ca2+ exerted a predominant effect on compactionas observed by
HPSEC, we used the AUC observations obtained for 1.1 mm Ca2+ with or without Mg2+ as
a statistical group for estimating its impact of the presence of Ca2+ on S20,w : we obtained a
value S20,w = 3.84 ± 0.014 Svedburgs (n=2) corresponding to R= 4.22 nm ± 0.014. In
summary, the sedimentation behavior obtained by AUC supports a stark compaction effect
by Ca2+ both observed by HPSEC and predicted by molecular modeling.
3.8. Estimation of the amount of compaction observed by HPSEC
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We used the values of R obtained by AUC for X2+ free pd-FIX and in the presence of 1.1
mm Ca2+ to estimate column parameters needed to predict the change in R from all other
HPSEC data. Fig. 8 shows a strong interpolative consistency for the R vs. Ca2+
concentration behavior using HPSEC values in the range of 0 to 1.1 mM Ca2+. These values
were trend-wise consistent with the remaining experimental values obtained by AUC not
used to calibrate column parameters. At a physiologic level of Ca2+ at about which half
maximal filling of Ca2+ specific sites occurs in the Gla domain, an overall decrease in R of
2.7% occurred relative to the X2+ free pd-FIX. An asymptotic decrease in R of about 5.6%
was observed by HPSEC resulting from the complete filling of X2+ sites at supraphysiologic
Ca2+ levels. The change in the Rg predicted by our modeling was similar at about 5%. In
summary, we have shown that the holoprotein compaction phenomena due to both Mg2+ and
Ca2+ can be quantitatively measured by HPSEC. Furthermore, the sensitivity of this
measurement provides new insight into the cooperative nature of the folding phenomena
between Gla and EGF1 domains not provided by previous studies using crystallography,
circular dichroism and light scattering [14,52-55].

Author Manuscript

3.10. Scope and Limitations of Determining Compaction with HPSEC and AUC
We have demonstrated the use of HPSEC calibrated by AUC for determining the X2+
dependent compaction of VKD proteins. HPSEC is a greatly more facile technique than
AUC for obtaining replicate analyses needed for statistical comparisons of data sets under
different conditions. While a significant disadvantage is that at least 25 μg of highly purified
material must be used to study the compaction with HPSEC, this material is fully
recoverable. Using these methods, we have demonstrated that HPSEC is capable of
detecting the changes in the radius of hydration on the scale of ~0.01 nm. The gradual filling
Anal Biochem. Author manuscript; available in PMC 2016 June 15.
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of X2+ sites in different domains of the VKD holoprotein can be detected on this scale due
to this sensitivity. Within a purified mixture of rFIX, we showed that HPSEC is grossly
capable of distinguishing between different levels of -carboxylated species due to
differences in compaction. This then enables HPSEC to be used for the fractionation of
subpopulations of VKD proteins from within the mixture.
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Fig. 1.
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Modeled structures of intact FIX without (A) and with (B) X2+ ions predicted from the
crystallographic data. The Gla, EGF1-like, EGF2-like and the protease domain in FIX are
colored red, yellow, purple and cyan, respectively. FIX contains 10 Ca2+/Mg2+ binding
sites, which are numbered 1 through 10; eight of these are in the Gla domain (number 1-8),
one in the EGF1-like domain (number 9) and one in the protease domain (number 10). The
Ca2+-specific sites are shown as green spheres, whereas the sites 1, 4, 7 and 8 could be
occupied by either Ca2+ or Mg2+ are shown as magenta spheres. As a result of X2+ binding,
a major structural change occurs in the Gla domain and a minor change in the EGF1-like
domain of FIX. The properly formed ω-loop is clearly visible and positioned below metal
sites 3, 4 and 5.
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Fig. 2.

Homogeneity and extent of aggregation of starting samples of purified FIX. SDS-PAGE and
HPSEC as a function of the injection amount was studied: A) Non-reducing SDS-PAGE of
purified FIX: Lane 1. Molecular weight markers; Lane 2. FIX (2 μg). Arrow indicates
proteolyzed pd-FIX. B) HPSEC chromatographic profiles of FIX at 25 μg (curve 1) and at
50 μg injected (curve 2) at physiologic 1.1 mM Ca2+ and C) HPSEC chromatographic
profiles of FIX at 25 μg (curve 1) and at 50 μg injected (curve 2) at physiologic 0.6 mM
Mg2+.
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Fig. 3.
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HPSEC residence time behavior of FIX in the presence of CaCl2 only. In each case, amount
of FIX injected was 100 μg. A) Curve 1: no X2+, Curve 2: 0.5 mM CaCl2, Curve 3: 1.1 mM
CaCl2, Curve 4: 5 mM CaCl2, Curve 5: 10 mM CaCl2, Curve 6: 15 mM CaCl2. B) Net
residence time shift in the HPSEC residence time by FIX with change in CaCl2
concentration in the range from 0 - 15 mM; inset, magnified view of residence time shift
induced in the range from 0 – 0.5 mM CaCl2. Each data point condition was performed in
triplicate with a standard deviation <0.016 minutes. Arrow indicates physiological levels of
CaCl2.
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Fig. 4.
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HPSEC residence time behavior of FIX in the presence of MgCl2 only. In each case, amount
of FIX injected was 100 μg. A) Curve 1: no X2+, Curve 2: 0.6 mM MgCl2, Curve 3: 5 mM
MgCl2, Curve 4: 10 mM MgCl2, Curve 5: 15 mM MgCl2. B) Net residence time shift in the
HPSEC residence time by FIX with change in MgCl2 concentration in the range from 0 - 15
mM. Each data point condition was performed in triplicate with a standard deviation <0.016
minutes. Arrow indicates physiological levels of MgCl2.

Author Manuscript
Anal Biochem. Author manuscript; available in PMC 2016 June 15.

Vanderslice et al.

Page 17

Author Manuscript
Fig. 5.
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HPSEC residence time behavior of FIX in the presence of physiologic levels of both CaCl2
and MgCl2: Curve 1: no X2+, Curve 2: 0.6 mM MgCl2, Curve 3: 1.1 mM CaCl2, Curve 4:
1.1 mM CaCl2 & 0.6 mM MgCl2. Each data point condition was performed in triplicates
with a standard deviation <0.016. Arrows indicate physiological levels of MgCl2 or CaCl2.
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Fig. 6.

HPSEC chromatogram of the fractionation of purified r-FIX populations. Table 1 presents
characterization of Peak 1 and Peak 2. Peak 1) low Gla, inactive r-FIX; Peak 2) high Gla,
active FIX; Peak 3) FIXa.
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Fig. 7.

HPSEC net residence time shift of r-FIX in the presence of 0-15 mM MgCl2 and CaCl2. In
each case, amount of r-FIX injected was 100 μg. A) 0-15 mM CaCl2 B) 0-0.5 mM CaCl2 C)
0-15 mM MgCl2 D) 0-1.1 mM MgCl2. Each data point condition was performed in triplicate
with a standard deviation <0.016 minutes. Arrows indicate physiological levels of MgCl2 or
CaCl2.
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Fig. 8.
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Estimated CaCl2-dependent change in Stokes radius of FIX as measured by HPSEC. R
values by HPSEC made by correlation method of Laurent and Killander [33], Acker [34],
and Fish and Reynolds et al. [35]. A) ◆ HPSEC Value; ▲ AUC Value B) ■ Percent change
in R estimated by HPSEC (%). Arrows indicate AUC values used to determine coefficient of
the HPSEC correlation.
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Total Gla content and activity of purified r-FIX populations fractionated by HPSEC.
Sample

Total Gla Content

% Gla

Activity (Units/mg)

% FIXa

pd-FIX

12 Gla

100

200

0

3

0

249

0

Peak 1

Peak 2

10 Gla

>30

6-9 Gla

<70

10-12 Gla

>80

8-9 Gla

<20
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Sedimentation coefficients and estimated Stokes radii from analytical centrifugation of FIX. The
sedimentation coefficient S is given for FIX centrifuged in the presence of EDTA, Ca2+ and/or Mg2+.
1

Author Manuscript

Solvent

S20,w (Svedberg)

Stokes Radius (nm)

10 mM EDTA

3.71

10 mM EDTA

3.72

10 mM EDTA

3.72

0.6 mM MgCl2

3.82

4.24

0.6 mM MgCl2 + 1.1 mM CaCl2

3.83

4.23

0.3 mM CaCl2

3.82

4.24

1.1 mM CaCl2

3.85

3.0 mM CaCl2

3.89

a

4.36

a

4.35

a

4.35

a

4.21
4.16

a

Used to determine coefficient of the SEC correlation by methods developed in Laurent and Killander (1964).

1

The buffer contained 50 mM Tris, 0.15 M NaCl, pH 7.5 and either EDTA or X2+ as indicated
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